Name: alzheimer's disease (en Inglés)
SKU: 24883278
Price: 3456.32 MXN
Availability: InStock
Author: Lau, Lit-Fui ; Brodney, Michael A.
ISBN: 9783642093548

Formato

Libro Físico

Ilustrado por

Lit-Fui Lau

Michael A. Brodney

Editorial

Springer

Autor

Lau, Lit-Fui ; Brodney, Michael A.

Año

2010

Idioma

Inglés

N° páginas

179

Encuadernación

Tapa Blanda

Dimensiones

23.4x15.6x1.1 cm

Peso

0.28 kg.

ISBN

364209354x

ISBN13

9783642093548

Categorías

Medicina preclínica: ciencias básicas
Farmacología
Bioquímica

alzheimer's disease (en Inglés)

Lit-Fui Lau (Ilustrado por) · Michael A. Brodney (Ilustrado por) · Springer · Tapa Blanda

Libro Nuevo Importado

Envío: 24 a 29 días háb.

$ 6,912.64$ 3,456.32

-50%

Costos de importación incluídos en el precio ✅

Libro Nuevo

Quedan 100 unidades

$ 3,456.32

¡Envío Gratis! Llega entre el 16 Oct y el 26 Oct a CUAUHTÉMOC, Ciudad de México. Seleccionar ubicación

Agregar a lista de deseos

Reseña del libro "alzheimer's disease (en Inglés)"

Alzheimer's disease (AD) is a neurodegenerative disease that robs the minds of our elderly population. Approximately one in every eight adults over the age of 65 and nearly half of those over 85 are afflicted with this disease. The aging population in developed societies will impose an ever increasing socioeconomic threat in the future. Current medicines for AD patients are mainly symptomatic treatments and a huge unmet medical need exists to slow the progression of this disease. A great deal of research has been dedicated to understanding the pathogenesis of AD from which comes many ideas for intervening with its progression. Some of these ideas have been fast-tracked to clinical trials due to the availability of medicines with proven clinical efficacies for other diseases (e.g. atorvastatin, simvastatin, rosiglitazone and clioquinol) while others represent novel chemical entities (e.g. glycogen synthase kinase-3 inhibitors). This volume will first review existing cholinesterase inhibitors prescribed for AD patients followed by some target mechanisms with ongoing clinical trials. It offers a glimpse of what our future medicine cabinets may look like for AD patients. It also provides an interesting read on why and how current medicines for other indications could potentially be used to treat AD.